TABLE 3.
Assessment of efficacy in ITT, clinically evaluable, and microbiologically evaluable patients
| Patient group | Treatment | Total no. (%) of patients assesseda | No. (%) of patients with assessment
|
P (95% CIb [point estimate])b | |
|---|---|---|---|---|---|
| Cure | Failurec | ||||
| ITT | Linezolid | 400 (100) | 279 (69.8) | 121 (30.8) | 0.141 (−1.58, 11.25 [4.9]) |
| Oxacillin-dicloxacillin | 419 (100) | 272 (64.9) | 147 (35.1) | ||
| Clinically evaluable | Linezolid | 298 (100) | 264 (88.6) | 34 (11.4) | 0.300 (−2.5, 8.2 [2.8]) |
| Oxacillin-dicloxacillin | 302 (100) | 259 (85.8) | 43 (14.2) | ||
| Microbiologically evaluable | Linezolid | 143 (100) | 126 (88.1) | 17 (11.9) | 0.606 (−5.6, 9.7 [2.0]) |
| Oxacillin-dicloxacillin | 151 (100) | 130 (86.1) | 21 (13.9) | ||
a
Percentages based on number of assessed patients.
b
Confidence interval based on normal approximation, expressed as a percentage.
c
Includes patients with missing or indeterminate outcomes.